Danaher Corporation (DHR) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers Danaher Corporation's quarterly report (Form 10-Q) for the period ended June 26, 2026. Danaher operates in three primary segments: Biotechnology, Life Sciences, and Diagnostics. The reporting period is defined by a significant strategic event: the acquisition of Masimo Corporation on June 10, 2026, for approximately $9.8 billion, which has been integrated into the Diagnostics segment.
Key Financial Metrics
| Metric ($ in millions) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Sales | $6,265 | $5,936 | $12,216 | $11,677 |
| Operating Profit | $1,127 | $760 | $2,471 | $2,034 |
| Net Earnings | $870 | $555 | $1,899 | $1,509 |
| Diluted EPS | $1.23 | $0.77 | $2.68 | $2.10 |
| Operating Cash Flow (YTD) | $2,856 (2026) vs $2,637 (2025) | |||
| Free Cash Flow (YTD) | $2,350 (2026) vs $2,144 (2025) | |||
| Total Debt (Long-term + Current) | $26,558 (as of June 26, 2026) | |||
| Cash and Equivalents | $4,348 (as of June 26, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 5.5% in Q2 and 4.5% YTD compared to 2025. Core sales (excluding acquisitions and currency) grew 3.0% in Q2 and 2.0% YTD. High-growth markets drove significant volume, increasing 15% in Q2.
- Profitability: Operating profit margins expanded significantly (18.0% in Q2 2026 vs. 12.8% in Q2 2025). This improvement is largely attributable to a $432 million impairment charge recorded in Q2 2025 related to a Life Sciences trade name, which is not present in the current period.
- Acquisition Impact: The Masimo acquisition contributed to sales growth but introduced one-time costs. Q2 2026 results include $74 million in nonrecurring acquisition-related charges (inventory fair value adjustments, transaction costs, and change-in-control payments).
- Debt Structure: Total debt increased from $18.4 billion (Dec 31, 2025) to $26.6 billion (June 26, 2026) to finance the Masimo acquisition. The company issued new Euro-denominated and Swiss Franc-denominated notes totaling approximately $6.5 billion in net proceeds during the period.
- Segment Performance:
- Biotechnology: Sales up 4.0% (Q2); driven by consumables demand.
- Life Sciences: Sales up 5.5% (Q2); operating profit turned positive ($244M) from a loss ($239M) in the prior year due to the absence of the 2025 impairment charge.
- Diagnostics: Sales up 7.0% (Q2); core sales excluding respiratory testing grew 5.0%, offsetting declines in respiratory testing demand.
Guidance, Outlook, and Risks
- Outlook: Management expects the effective tax rate for the remainder of 2026 to be approximately 17.0%. The company anticipates continued growth in high-growth markets and integration benefits from Masimo.
- Tariff Environment: Following a U.S. Supreme Court ruling in February 2026 regarding the International Emergency Economic Powers Act (IEEPA), the company is pursuing refunds for tariffs paid in prior periods. New tariffs implemented under alternative authority remain a source of uncertainty.
- Geopolitical Risks: Ongoing conflict in the Middle East has caused supply chain delays and increased logistics costs, though no material operational interruptions were reported in H1 2026.
- Legal Contingencies:
- Masimo Litigation: Danaher inherited significant legal matters from Masimo, including a $634 million jury verdict against Apple (pending final judgment) and a DOJ investigation regarding Rad-G/Rad-97 products.
- Hawkins Litigation: A securities class action regarding bioprocessing revenue disclosures has reached a preliminary settlement approval.
- Capital Allocation: The company repurchased approximately 5.0 million shares for $903 million in the first half of 2026. Dividends increased to $0.40 per share in Q2 2026.
Investor Verification Checklist
- Masimo Integration: Verify the timeline for realizing synergies and the impact of Masimo's recurring revenue mix on the Diagnostics segment's long-term margins.
- Debt Servicing: Assess the impact of the increased debt load ($26.6B) on interest expense and credit ratings, particularly given the mix of fixed and floating rate instruments.
- Respiratory Testing Volatility: Monitor the "Core sales excluding respiratory testing" metric to gauge underlying demand trends in the Diagnostics segment, as respiratory sales remain cyclical.
- Tariff Refunds: Track the realization of IEEPA tariff refunds and the potential impact of new tariffs on gross margins in future quarters.
- Legal Reserves: Review the adequacy of reserves for the Masimo-related litigation (Apple, DOJ, Kiani) and the Hawkins settlement, as outcomes could materially affect future earnings.